Overview of Whole Genome Synthesis MarketThe global Whole Genome Synthesis Market is valued at USD 2.41 Billion in 2024 and is projected to reach a value of USD 12.21 Billion by 2035 at a CAGR ...
Intellia Therapeutics will find it challenging to survive now that its CRISPR gene-editing treatment has been tied to severe, ...
Intellia Therapeutics said it is pausing two late-stage CRISPR gene-editing trials after a patient in one study was hospitalized with liver damage.
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...
A lthough still in its early days, CRISPR has already been called the most powerful scientific tool of the century. Using ...
Advances in cancer immunotherapy from immune checkpoint modulation to adoptive cell transfer of tumour-infiltrating ...
Crispr Therapeutics (($CRSP)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled A Long-term Follow-up ...
Explore smart portfolio rebalancing as Comfort Systems USA (FIX) surges. Learn if it's time to shift profits to undervalued ...
Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback